442 related articles for article (PubMed ID: 31057298)
1. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data.
Guo GF; Wang YX; Zhang YJ; Chen XX; Lu JB; Wang HH; Jiang C; Qiu HQ; Xia LP
World J Gastroenterol; 2019 Apr; 25(15):1840-1853. PubMed ID: 31057298
[TBL] [Abstract][Full Text] [Related]
2. Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer.
Guo GF; Jiang WQ; Zhang B; Cai YC; Xu RH; Chen XX; Wang F; Xia LP
World J Gastroenterol; 2011 Nov; 17(43):4779-86. PubMed ID: 22147978
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of autophagy-related markers LC3, p62/sequestosome 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status.
Schmitz KJ; Ademi C; Bertram S; Schmid KW; Baba HA
World J Surg Oncol; 2016 Jul; 14(1):189. PubMed ID: 27444698
[TBL] [Abstract][Full Text] [Related]
4. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
[TBL] [Abstract][Full Text] [Related]
5. Tumour location and efficacy of first-line EGFR inhibitors in
Benavides M; Díaz-Rubio E; Carrato A; Abad A; Guillén C; Garcia-Alfonso P; Gil S; Cano MT; Safont MJ; Gravalos C; Manzano JL; Sánchez A; Alcaide J; López R; Massutí B; Sastre J; Martínez E; Escudero P; Méndez M; Aranda E
ESMO Open; 2019; 4(6):e000599. PubMed ID: 31803504
[TBL] [Abstract][Full Text] [Related]
6. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
7. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
8. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous activation of impaired autophagy and the mammalian target of rapamycin pathway in oral squamous cell carcinoma.
Yin X; Hu L; Feng X; Wang H; Zhang C; Wang H; Wang S
J Oral Pathol Med; 2019 Sep; 48(8):705-711. PubMed ID: 31132188
[TBL] [Abstract][Full Text] [Related]
10. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
11. Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.
Chen Y; Shi Y; Lin J; Ye YB; Wang XJ; Chen G; Guo ZQ
Medicine (Baltimore); 2015 Oct; 94(40):e1698. PubMed ID: 26448020
[TBL] [Abstract][Full Text] [Related]
12. Autophagy-related genes Raptor, Rictor, and Beclin1 expression and relationship with multidrug resistance in colorectal carcinoma.
Shuhua W; Chenbo S; Yangyang L; Xiangqian G; Shuang H; Tangyue L; Dong T
Hum Pathol; 2015 Nov; 46(11):1752-9. PubMed ID: 26363527
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer.
Pichler M; Winter E; Stotz M; Eberhard K; Samonigg H; Lax S; Hoefler G
Br J Cancer; 2012 May; 106(11):1826-32. PubMed ID: 22549179
[TBL] [Abstract][Full Text] [Related]
14. Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer.
Fiala O; Sorejs O; Hosek P; Liska V; Vycital O; Bruha J; Kucera R; Topolcan O; Finek J; Maceckova D; Pitule P
Cancer Genomics Proteomics; 2020; 17(5):605-613. PubMed ID: 32859639
[TBL] [Abstract][Full Text] [Related]
15. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
[TBL] [Abstract][Full Text] [Related]
16. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
De Cuyper A; Van Den Eynde M; Machiels JP
Clin Colorectal Cancer; 2020 Jun; 19(2):65-72. PubMed ID: 32229076
[TBL] [Abstract][Full Text] [Related]
17. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Hatch AJ; Sibley AB; Starr MD; Brady JC; Jiang C; Jia J; Bowers DL; Pang H; Owzar K; Niedzwiecki D; Innocenti F; Venook AP; Hurwitz HI; Nixon AB;
Cancer Med; 2016 Sep; 5(9):2249-60. PubMed ID: 27465221
[TBL] [Abstract][Full Text] [Related]
18. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab.
Campanella C; Mottolese M; Cianciulli A; Torsello A; Merola R; Sperduti I; Melucci E; Conti S; Diodoro MG; Zeuli M; Paoletti G; Cognetti F; Garufi C
J Transl Med; 2010 Apr; 8():36. PubMed ID: 20398370
[TBL] [Abstract][Full Text] [Related]
20. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]